The FDA is slated to make a decision on whether to approve Pfizer’s shot in August before respiratory syncytial virus season in the fall.
FDA advisors recommend Pfizer’s RSV vaccine for infants but raise safety concerns
Share This Story, Choose Your Platform!
About the Author: David Hilbern
